Sponsors

Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. The company's mission is to create new standards of care in neurology, oncology and immunology through pioneering research, global development, manufacturing and commercial capabilities. At the heart of Biogen Idec's growth strategy is a long-standing focus on addressing serious unmet medical needs.

Currently, Biogen Idec markets three major therapies and has a product development pipeline that includes 15 products in Phase II clinical trials and beyond. Major products are TYSABRI® (natalizumab), for relapsing forms of MS; AVONEX® (Interferon beta-1a), for relapsing forms of MS; and RITUXAN® (rituximab), for non-Hodgkin's lymphoma and rheumatoid arthritis. In recent years, research and development efforts have been expanded into new therapeutic areas such as cardiovascular disease and hemophilia.

Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland and additional offices in the U.S., Canada, Australia, Japan and throughout Europe plus operations in Argentina, Brazil, China and India.